What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence suggests that brexucabtagene autoleucel may extend survival and improve response rates compared to standard care, but the lack of direct comparative data and the immaturity of survival data limit the strength of this conclusion. The committee noted short follow-up and small sample sizes as significant concerns.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness analysis indicates that brexucabtagene autoleucel could be cost-effective under certain conditions, with an ICER below £50,000 per QALY gained. However, the estimates are sensitive to various assumptions, particularly regarding mortality risk and patient age.
Is there quality-of-life evidence payers weigh? — Quality of life
There is uncertainty regarding the impact of brexucabtagene autoleucel on HRQoL. The evidence does not clearly demonstrate improvements in quality of life, and the committee expressed concerns about the assumptions made regarding long-term survivors’ HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Brexucabtagene autoleucel has a manageable safety profile, although serious adverse effects are acknowledged. The committee noted that patients are willing to accept risks for potential curative outcomes, indicating a generally acceptable safety profile.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was not directly compared to the most common alternative, R-BAC, which raises concerns about the robustness of the evidence. The committee acknowledged that the standard of care is not uniformly accepted, which complicates the comparison.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is generally representative of the intended patient population, although there are concerns about the generalizability of results due to the trial’s exclusion of UK patients. However, the committee concluded that the results are likely applicable to the Healthcare population.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Brexucabtagene autoleucel can be integrated into existing treatment pathways with manageable adjustments. The committee noted that while some infrastructure may be needed, the treatment aligns well with current practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of brexucabtagene autoleucel are significant, but the potential for cost-effectiveness under certain conditions is acknowledged. The committee noted that the treatment could lead to high resource use, raising concerns about budget impact.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is limited by the ongoing nature of the ZUMA-2 trial and the lack of robust comparative data. The committee highlighted significant uncertainties and the need for further data to strengthen the evidence base.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term effectiveness and safety of brexucabtagene autoleucel, particularly concerning the age of patients and their HRQoL. The committee recognized these uncertainties could impact decision-making.
